Hypereosinophilic Syndrome Drug Market
Global Hypereosinophilic Syndrome drug Market Size, Share & Trends Analysis Report by Type (Benralizumab, Dasatinib, Dexpramipexole Dihydrochloride, Mepolizumab, Others), and by Application (Hospital, Clinics, Others) Forecast 2022-2028 Update Available - Forecast 2024-2030
The global hypereosinophilic syndrome drug market is anticipated to grow at a significant CAGR during the forecast period. Hypereosinophilic syndrome is a disorder that affects a person with a rise in the number of eosinophils and affects the immune system. With the rise in eosinophils, it affects the human body and results in a fatal condition. The global hypereosinophilic syndrome drug market is growing due to the rising focus of the major market players on developing new and effective treatments. Their increasing focus and expenditure on research and development to launch advance product for the treatment is also boosting the market growth. The rising government support and the development of healthcare infrastructure is also helping the market to grow. However, the lack of knowledge among the population in the developing countries and the cost of are the restraining factor for the market. The development of advance therapeutics and the increasing number of market players with their drug pipeline will contribute the market to grow in the forecast period.
Impact of COVID-19 Pandemic on Global Hypereosinophilic Syndrome Drug Market
The COVID-19 pandemic has impacted the market in a positive way. This is because eosinophils are associated with acute respiratory deterioration. As the COVID-19 virus had several acute respiratory and lungs problems, the global demand of hypereosinophilic syndrome drug market increased as patients were more prevailed to have the hypereosinophilic syndrome during the COVID-19. However, the medical device manufacturer were struggling to get clinical data for the development of new device as the healthcare facilities were facing major challenges in treating COVID-19 patients.
Segmental Outlook
The global hypereosinophilic syndrome drug market is segmented based on the type and application. Based on the type, the market is segmented into benralizumab, dasatinib, dexpramipexole dihydrochloride, mepolizumab, others. Amongst the type, benralizumab hypereosinophilic syndrome drug is anticipated to propel the growth of the market over the forecast period. Based on the application, the market is sub-segmented into hospital, clinics, and others. Amongst the application, the hospital treated hypereosinophilic syndrome drug market is anticipated to grow more in the forecasted period. The above-mentioned segments can be customized as per the requirements.
Global Hypereosinophilic syndrome drug Market Share by Type, 2022 (%)
The Benralizumab Hypereosinophilic Syndrome Drug is Anticipated to Hold a Prominent Share in the Global Hypereosinophilic syndrome drug Market
The benralizumab hypereosinophilic syndrome drug market is anticipated to hold the major share in the global hypereosinophilic syndrome drug market. Eosinophils play a vital role in the inflammatory pathology of asthma. Benralizumab is prescribed to treat patients with severe and uncontrolled asthma along with eosinophilic inflammation. The integrated analyses of benralizumab safety from the clinical phase III trials of SIROCCO and CALIMA to treat patients of asthma and chronic pulmonary disease is successful. Benralizumab is anticipated to hold the major market share due to their increase advantages over other hypereosinophilic syndrome drugs. The Institute for Clinical and Economic Review also approved the clinical effectiveness and cost effectiveness of benralizumab drugs will boost the global hypereosinophilic syndrome drug market to grow in the forecasted period.
Regional Outlooks
The global hypereosinophilic syndrome drug market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, and Others), and the Rest of the World (the Middle East &Africa, and Latin America. The North American hypereosinophilic syndrome drug market is expected to hold prominent share in the global hypereosinophilic syndrome drug market.
Global Hypereosinophilic syndrome drug Market Growth, by Region 2022-2028
The North America Region is Estimated to Hold the Major Share in the Global Hypereosinophilic syndrome drug Market
North America is anticipated to hold the major share in the global hypereosinophilic syndrome drug market. This is due to the high prevalence of autoimmune disorders in this region. The increasing number of cancer patients and high awareness about various blood disorders is also boosting the growth of the North American hypereosinophilic syndrome drug market. According to the America Autoimmune Related Disease Association, around 50 million Americans suffered from autoimmune disorders in 2017 and the number is still rising. According to American Cancers Society’s, in 2018, an estimation of 1,735,350 new cancer cases were registered and 609,640 deaths were registered. The hypereosinophilic syndrome drug market in Asia-Pacific region will hold the fastest share due to the increasing awareness and developing healthcare infrastructure of this region.
Market Players Outlook
The major companies serving the global hypereosinophilic syndrome drug market include Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Novartis AG, Kyowa Kirin Co. Ltd., and many more. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches for the advancement of the treatment, to stay competitive in the market. For instance, in September 2020, GlaxoSmithKline Plc. announced their approval of Nucala from USFDA that will be used for the treatment of hypereosinophilic syndrome for more than six months without an identifiable non-hematology cause in adults.
The Report Covers
- Market value data analysis of 2022 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global hypereosinophilic syndrome drug market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on The Global Hypereosinophilic Syndrome Drug Market
• Recovery Scenario of Global Hypereosinophilic Syndrome Drug Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Bristol-Myers Squibb Co.
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. F. Hoffmann-La Roche Ltd.
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. GlaxoSmithKline Plc.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Kyowa Kirin Co. Ltd.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Novartis AG
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Hypereosinophilic Syndrome Drug Market by Type
4.1.1. Benralizumab
4.1.2. Dasatinib
4.1.3. Dexpramipexole Dihydrochloride
4.1.4. Mepolizumab
4.1.5. Others
4.2. Global Hypereosinophilic Syndrome Drug Market by Application
4.2.1. Hospital
4.2.2. Clinic
4.2.3. Others
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. AstraZeneca
6.2. Knopp Biosciences LLC
6.3. Stemline Therapeutics Inc.
1. GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021 - 2028 ($ MILLION)
2. GLOBAL BENRALIZUMAB HYPEREOSINOPHILIC SYNDROME DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021 - 2028 ($ MILLION)
3. GLOBAL DASATINIB HYPEREOSINOPHILIC SYNDROME DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021 - 2028 ($ MILLION)
4. GLOBAL DEXPRAMIPEXOLE DIHYDROCHLORIDE HYPEREOSINOPHILIC SYNDROME DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021 - 2028 ($ MILLION)
5. GLOBAL MEPOLIZUMAB HYPEREOSINOPHILIC SYNDROME DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021 - 2028 ($ MILLION)
6. GLOBAL OTHERS HYPEREOSINOPHILIC SYNDROME DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021 - 2028 ($ MILLION)
7. GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021 - 2028 ($ MILLION)
8. GLOBAL HOSPITAL TREATED HYPEREOSINOPHILIC SYNDROME DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021 - 2028 ($ MILLION)
9. GLOBAL CLINICALLY TREATED HYPEREOSINOPHILIC SYNDROME DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021 - 2028 ($ MILLION)
10. GLOBAL OTHERS TREATED HYPEREOSINOPHILIC SYNDROME DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021 - 2028 ($ MILLION)
11. GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021 - 2028 ($ MILLION)
12. NORTH AMERICAN HYPEREOSINOPHILIC SYNDROME MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021 - 2028 ($ MILLION)
13. NORTH AMERICAN HYPEREOSINOPHILIC SYNDROME MARKET RESEARCH AND ANALYSIS BY TYPE, 2021 - 2028 ($ MILLION)
14. NORTH AMERICAN HYPEREOSINOPHILIC SYNDROME MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021 - 2028 ($ MILLION)
15. EUROPEAN HYPEREOSINOPHILIC SYNDROME MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021 - 2028 ($ MILLION)
16. EUROPEAN HYPEREOSINOPHILIC SYNDROME MARKET RESEARCH AND ANALYSIS BY TYPE, 2021 - 2028 ($ MILLION)
17. EUROPEAN HYPEREOSINOPHILIC SYNDROME MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021 - 2028 ($ MILLION)
18. ASIA-PACIFIC HYPEREOSINOPHILIC SYNDROME MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021 - 2028 ($ MILLION)
19. ASIA-PACIFIC HYPEREOSINOPHILIC SYNDROME MARKET RESEARCH AND ANALYSIS BY TYPE, 2021 - 2028 ($ MILLION)
20. ASIA-PACIFIC HYPEREOSINOPHILIC SYNDROME MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021 - 2028 ($ MILLION)
21. REST OF THE WORLD HYPEREOSINOPHILIC SYNDROME MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021 - 2028 ($ MILLION)
22. REST OF THE WORLD HYPEREOSINOPHILIC SYNDROME MARKET RESEARCH AND ANALYSIS BY TYPE, 2021 - 2028 ($ MILLION)
23. REST OF THE WORLD HYPEREOSINOPHILIC SYNDROME MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021 - 2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET, 2021 - 2028($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET BY SEGMENT, 2021 - 2028($ MILLION)
3. RECOVERY OF GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET, 2021-2027 (%)
4. GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5. GLOBAL BENRALIZUMAB HYPEREOSINOPHILIC SYNDROME MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL DASATINIB HYPEREOSINOPHILIC SYNDROME MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL DEXPRAMIPEXOLE DIHYDROCHLORIDE HYPEREOSINOPHILIC SYNDROME MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL MEPOLIZUMAB HYPEREOSINOPHILIC SYNDROME MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL OTHERS HYPEREOSINOPHILIC SYNDROME MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
11. GLOBAL HOSPITAL TREATED HYPEREOSINOPHILIC SYNDROME MAREKT SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL CLINICALLY TREATED HYPEREOSINOPHILIC SYNDROME MAREKT SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL OTHERS TREATED HYPEREOSINOPHILIC SYNDROME MAREKT SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. US GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SIZE, 2021 - 2028($ MILLION)
16. CANADA GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SIZE, 2021 - 2028($ MILLION)
17. UK GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SIZE, 2021 - 2028($ MILLION)
18. FRANCE GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SIZE, 2021 - 2028($ MILLION)
19. GERMANY GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SIZE, 2021 - 2028($ MILLION)
20. ITALY GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SIZE, 2021 - 2028($ MILLION)
21. SPAIN GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SIZE, 2021 - 2028($ MILLION)
22. REST OF EUROPE GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SIZE, 2021 - 2028($ MILLION)
23. INDIA GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SIZE, 2021 - 2028($ MILLION)
24. CHINA GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SIZE, 2021 - 2028($ MILLION)
25. JAPAN GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SIZE, 2021 - 2028($ MILLION)
26. REST OF ASIA-PACIFIC GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SIZE, 2021 - 2028($ MILLION)
27. REST OF THE WORLD GLOBAL HYPEREOSINOPHILIC SYNDROME DRUG MARKET SIZE, 2021 - 2028($ MILLION)
